Abstracts tagged "Anti-CCP"

Abstract Number: 0564 • ACR Convergence 2021
Associations of Sinusitis, Pharyngitis, and Respiratory Tract Disease Burden with Incident Rheumatoid Arthritis
Vanessa Kronzer¹, Weixing Huang², Alessandra Zaccardelli², Cynthia Crowson³, John Davis¹, Robert Vassallo¹, Tracy Doyle⁴, Elena Losina² and Jeffrey Sparks², ¹Mayo Clinic, Rochester, MN, ²Brigham and Women's Hospital, Boston, MA, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Increasing evidence implicates respiratory mucosa in the pathogenesis of rheumatoid arthritis (RA). However, individual respiratory tract diseases, especially of the upper airways, sinuses, and…
Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Amy Joseph¹, Jodi Yanagida¹, Xinliang Huang¹, Prabha Ranganathan¹, Melissa Laurie², Hong Xian¹ and Seth Eisen¹, ¹VA St. Louis Health Care System, St. Louis, MO, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
Abstract Number: 0590 • ACR Convergence 2021
Association of Lipid Mediator Profiles and Development of Future Incident Inflammatory Arthritis in a High Risk, Anti-citrullinated Protein Antibody Positive Population
Lauren Vanderlinden¹, Elizabeth Bemis², Kristen Polinski³, Kristen Demoruelle⁴, Marie Feser⁵, Jennifer Seifert⁶, Ted Mikuls⁷, Michael Weisman⁸, Jane Buckner⁹, Kevin Deane¹⁰, Michael Clare-Salzler¹¹, V. Michael Holers¹² and Jill Norris¹³, ¹Colorado School of Public Health, Monument, CO, ²Colorado School of Public Health Anschutz Medical Campus, Aurora, CO, ³CSPH, Gaithersburg, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado School of Medicine, Littleton, CO, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰University of Colorado Denver, Denver, CO, ¹¹Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, ¹²University of Colorado, Denver, CO, ¹³Colorado School of Public Health, Aurora, CO
Background/Purpose: Lipid mediators are endogenously derived from the metabolism of omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) and have important roles in promoting and resolving…
Abstract Number: 1200 • ACR Convergence 2021
Predicting Progression to RA in Patients with Seropositive Arthralgia
Aine Gorman¹, Keelin Flynn², Matthew Turk¹, Candice Low³, Kieran Murray⁴, Carl Orr⁵, Phil Gallagher⁵, Lorna Freeman², Edel Meaney², Eamonn Molloy⁶, Lorraine O Neill⁷, Ursula Fearon⁸ and Douglas Veale⁹, ¹St Vincents Hospital, Dublin, Ireland, ²The Centre for Arthritis and Rheumatic Disease, EULAR Centre of Excellence, St. Vincent’s University Hospital and University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶St Vincent's Healthcare Group, Dublin, Ireland, ⁷St. Vincent's Hospital, Dublin, Ireland, ⁸Trinity College Dublin, Dublin, Ireland, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory condition often associated with joint destruction, disability, and reduced life expectancy. Before RA diagnosis, some patients may…
Abstract Number: 1206 • ACR Convergence 2021
Serum Levels of Total IgA Anti-cyclic Citrullinated Protein Antibodies Predict 11-year Radiographic Outcome in Early Rheumatoid Arthritis
Elisabeth Rasmussen¹, Liv Thiele¹, Kristian Stengaard-Pedersen², Merete Hetland³, Kim Horslev-Petersen⁴, Peter Junker⁵, Mikkel Ostergaard⁶, Aida Hansen¹, Malene Hvid¹, Bent Deleuran¹ and Stinne Greisen¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University Hospital, Aarhus, Denmark, ³DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁴Danish Hospital for Rheumatic Diseases, Haderslev, Denmark, ⁵Department of Rheumatology, Odense University Hospital, University of Southern Denmark, Odense M, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular synovitis and frequent occurrence of autoantibodies, playing a central role in disease progression. Anti-citrullinated peptide antibodies (ACPA)…
Abstract Number: 1230 • ACR Convergence 2021
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Jeffrey Sparks², Arnaud Constantin³, Ricardo Xavier⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Toulouse University Hospital, Toulouse Cedex 9, France, ⁴Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵AbbVie Inc., North Chicago, IL, ⁶University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
Abstract Number: 0042 • ACR Convergence 2021
High-throughput Testing for Modified-protein Antibodies in Patients Diagnosed with “Seronegative” Rheumatoid Arthritis
Michael Richter¹, Hari Krishnamurthy², Sylvia Posso³, Jeffrey Carlin⁴ and Jane Buckner³, ¹University of Washington, Mercer Island, WA, ²Vibrant Sciences, San Carlos, CA, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Virginia Mason Medical Center, Seattle, WA
Background/Purpose: Antibodies to citrullinated and other modified proteins play a critical role in the pathogenesis of rheumatoid arthritis (RA). The prevalence and degree of multi-site…
Abstract Number: 0181 • ACR Convergence 2021
Magnetic Resonance Imaging Findings in Early Rheumatoid Arthritis: Are There Differences Based on Autoantibody Status?
Caitrin Coffey¹, Gavin McKenzie¹, Nicholas Rhodes¹, Cassondra Hulshizer¹, Cynthia Crowson², John Davis¹ and Kerry Wright¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: Magnetic resonance imaging (MRI) is increasingly used as an adjunct to the physical examination in early rheumatoid arthritis (RA). Characteristic differences in MRI findings…
Abstract Number: 0273 • ACR Convergence 2021
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…
Abstract Number: 0440 • ACR Convergence 2021
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Kristen Mathias¹, Marco Lopez Velazquez¹ and Pankti Reid², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
Abstract Number: 0455 • ACR Convergence 2021
Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients
Juergen Rech¹, Mikkel Ostergaard², Koray Tascilar³, Melanie Hagen⁴, Larissa Valor Mendez⁴, Arnd Kleyer⁴, Gerhard Kroenke⁴, David Simon⁵, Verena Schoenau⁴, Axel Hueber⁶, Stefan Kleinert⁷, Xenofon Baraliakos⁸, Martin Fleck⁹, Andrea Rubbert-Roth¹⁰, Frank Behrens¹¹, David Kofler¹², Martin Feuchtenberger¹³, Michael Zaenker¹⁴, Reinhard Voll¹⁵, Cornelia Glaser¹⁶, Eugen Feist¹⁷, Gerd Burmester¹⁸, Kirsten Karberg¹⁹, Johannes Strunk²⁰, Juan D Cañete²¹, Esperanza Naredo²², Maria Filkova²³, Ladislav Senolt²⁴ and Georg Schett²⁵, ¹Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Germany, Erlangen, Germany, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ³Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁴Friedrich-Alexander University (FAU) Erlangen-Nuernberg and Universitaetsklinikum Erlangen, Medical Department 3, Rheumatology & Immunology, Erlangen, Germany, ⁵Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ⁶sozialstiftung-bamberg.de, Bamberg, Germany, ⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Asklepios Klinikum Bad Abbach Klinik und Poliklinik für Rheumatologie/ Klin. Immunologie, Bad Abbach, Germany, ¹⁰Kantonspital St Gallen, St.Gallen, Switzerland, ¹¹Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ¹²Division of Rheumatology and Clinical Immunology, Department I of Internal Medicine; University Hospital Cologne, Cologne, Germany, ¹³MED | BAYERN OST GmbH Fachbereich Rheumatologie, Burghausen, Germany, ¹⁴Immanuel Klinikum Bernau Herzzentrum Brandenburg, Bernau, Germany, ¹⁵Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹⁶Universitätsklinikum Freiburg Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ¹⁷Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ¹⁸Charité University Medicine Berlin, Berlin, Germany, ¹⁹Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, ²⁰Krankenhaus Porz am Rhein GmbH Rheumaklinik, Köln (Porz), Germany, ²¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, ²²Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain, ²³Institute of Rheumatology and Connective Tissue Research Laboratory, Department of Rheumatology of First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²⁵Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Rheumatoid arthritis (RA) has a preclinical phase that is characterized by the presence of antibodies against citrullinated proteins (ACPA), subclinical arthritis and pain. ACPA…
Abstract Number: 0463 • ACR Convergence 2021
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Sang Hee Park¹, Taylor Schwartz², Xue Han¹, Scott Robinson², Sumie Kakehi¹, Keith Wittstock¹, Kris Norris², Anne Murunga², Alison Silverstein² and Jeffrey Sparks³, ¹Bristol Myers Squibb, Princeton, NJ, ²Avalere Health, Washington, DC, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
Abstract Number: 0479 • ACR Convergence 2020
Early DAS Response After DMARD-start Increases Probability of Achieving Sustained DMARD-free Remission in Rheumatoid Arthritis
Marloes Verstappen¹, Ellis Niemantsverdriet², Xanthe Matthijssen², Saskia le Cessie² and Annette van der Helm - van Mil³, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands
Background/Purpose: Sustained DMARD-free remission (SDFR) is increasingly achievable. The pathogenesis underlying SDFR-development is unknown and patient-characteristics at diagnosis poorly explain whether SDFR will be achieved.…
Abstract Number: 0755 • ACR Convergence 2020
Exploring the Significance of Anti-Nuclear Antibody Positivity in the Medical Management of Patients with Rheumatoid Arthritis
Sujaytha Paknikar¹, Cynthia Crowson², John Davis¹ and Uma Thanarajasingam¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: ANA testing has been a well-established screening tool for autoimmune conditions such as SLE. Current practice for classification of RA does not include ANA…
Abstract Number: 0760 • ACR Convergence 2020
X-rays Bone Erosions Are Uncommon in Anti-CCP Positive Individuals At-risk of Rheumatoid Arthritis with Musculoskeletal Symptoms Without Clinical Synovitis, and Do Not Predict the Development of Inflammatory Arthritis
Andrea Di Matteo¹, Kulveer Mankia¹, Jacqueline L Nam¹, Edoardo Cipolletta², Leticia Garcia-Montoya³, Laurence Duquenne¹, Emma Rowbotham⁴ and Paul Emery⁵, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²Polytechnic University of Marche, Rheumatology Unit, Department of Clinical and Molecular Sciences, "Carlo Urbani" Hospital, Jesi (AN), Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ⁴Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: In individuals at-risk of RA, the identification of reliable biomarkers for the future development of clinical arthritis is of critical importance for risk-stratification and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].